BiotechTube

Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hepatocellular Carcinoma

Conditions

Hepatocellular Carcinoma

Trial Timeline

Aug 1, 2010 → Oct 1, 2013

NCT ID
NCT01098760

About Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment

Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment is a approved stage product being developed by Bayer for Hepatocellular Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01098760. Target conditions include Hepatocellular Carcinoma.

What happened to similar drugs?

4 of 20 similar drugs in Hepatocellular Carcinoma were approved

Approved (4) Terminated (2) Active (15)
✅LenvatinibEisaiApproved
✅Epirubicin + lipiodolJohnson & JohnsonApproved
✅Xenetix-CT perfusion imagingGuerbetApproved
✅Gadoterate meglumineGuerbetApproved
🔄Ramucirumab + PlaceboEli LillyPhase 3
🔄Atezolizumab + Bevacizumab + TiragolumabChugai PharmaceuticalPhase 3
🔄Tivantinib + PlaceboDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01098760ApprovedCompleted

Competing Products

20 competing products in Hepatocellular Carcinoma

See all competitors
ProductCompanyStageHype Score
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
26
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
26
Ramucirumab + PlaceboEli LillyPhase 3
40
ERY974 + Tocilicumab + Atezolizumab + BevacizumabChugai PharmaceuticalPhase 1
33
Atezolizumab + Bevacizumab + TiragolumabChugai PharmaceuticalPhase 3
44
GC33(RO5137382) + SorafenibChugai PharmaceuticalPhase 1
29
CS-1008 2 mg/kg + Sorafenib + CS-1008 6/2 mg/kg + CS-1008 6/6 mg/kg + CS-1008 4 mg/kg + CS-1008 6 mg/kgDaiichi SankyoPhase 2
35
Tivantinib + PlaceboDaiichi SankyoPhase 3
40
OSI-906 + PlaceboAstellas PharmaPhase 2
27
Enzalutamide + PlaceboAstellas PharmaPhase 2
35
Enzalutamide + Enzalutamide with SorafenibAstellas PharmaPhase 1
29
Recombinant oncolytic virus M1, anti PD-1 antibody, ApatinibSun PharmaceuticalPhase 1
25
Irinotecan + Sonidegib + SorafenibSun PharmaceuticalPhase 2
42
mFOLFOX7 combined with Camrelizumab and apatinibSun PharmaceuticalPhase 2
42
camrelizumab& apatinibSun PharmaceuticalPhase 2
31
LenvatinibEisaiPre-clinical
26
Lenvatinib PillEisaiPhase 2
39
Sorafenib + SorafenibEisaiPhase 1/2
32
LenvatinibEisaiPhase 2
42
Lenvatinib + NivolumabEisaiPhase 2
35